Prof. Bernard Lerer M.D.

LererAppointment: Professor of Psychiatry; Director, Biological Psychiatry Laboratory

Area of expertise: Behavioral and biochemical psychopharmacology, molecular neurobiology and neurogenetics.

Tel: 02-6777185; Email:


Selected Research Publications

Alkelai A, Greenbaum L, Rigbi A, Kanyas K, Lerer B (2009) Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology (Berl) 206(3):491-499

Cooper-Kazaz R, van der Deure WM, Medici M, Visser TJ, Alkelai A, Glaser B, Peeters RP, Lerer B (2009) Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine. J Affect Disord 116(1) 113-116

Greenbaum L, Smith R, Rigbi A, Strous R, Teltsh O, Kanyas K, Korner M, Lancet D, Ben-Asher E, Lerer B (2009) Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: Protective role of a functional polymorphism in the untranslated region. Pharmacog J 9(2):103-110

Eitan R, Landshut G, Lifschytz T, Einstein O, Ben-Hur T, Lerer B (2010) The thyroid hormone, triiodothyronine, enhances fluoxetine-induced neurogenesis in rats: Possible role in antidepressant-augmenting properties. Int J Neuropsychop 13(05):553-561

Greenbaum L, Alkelai A, Rigbi A, Kohn Y, Lerer B (2010) Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia. Mov Disord 25(16):2809-2817

Lifschytz T, Goltser-Dubner T, Landshut G, Lerer B (2010) Effect of triiodothyronine on 5-HT1A and 5-HT1B receptor expression in rat forebrain and on latency to feed in the novelty suppressed feeding test. Prog Neuropsychoph Biol Psychiatry 34(4):632-638

Lifschytz T, Zozulinsky P, Eitan R, Landshut G, Ohayon S, Lerer B (2010) Effect of triiodothyronine on antidepressant screening tests in mice and on presynaptic 5-HT1A receptors: Mediation by thyroid hormone receptors. J Pharmacol Exp Ther 337(2):494-502

Rigbi A, Yakir A, Sarner-Kanyas K, Pollak Y, Lerer B (2010) Why do young women smoke? VI. A controlled study of nicotine effects on attention: Pharmacogenetic interactions. Pharmacog J  11(1):45-52

Slonimsky A, Levy I, Kohn Y, Rigbi A, Ben-Asher E, Lancet D, Agam G, Lerer B (2010) Lymphoblast and brain expression of AHI1 and the novel primate-specific gene, C6orf217, in schizophrenia and bipolar disorder. Schizophr Res 120(1):159-166

Alkelai A, Lupoli S, Greenbaum L, Kohn Y, Kanyas-Sarner K, Ben-Asher E, Lancet D, Macciardi F, Lerer B (2011) DOCK4 and CEACAM21 as novel schizophrenia candidate genes in the Jewish population. Int J Neuropsychop  15(04):459-469

Vardi N, Freedman N, Lester H, Gomori JM, Chisin R, Lerer B, Bonne O (2011) Hyperintensities on T2-weighted images in the basal ganglia of patients with major depression: Cerebral perfusion and clinical implications. Psychiatry Res. Neuroimaging 192(2):125-130

Alkelai A, Greenbaum L, Lupoli S, Kohn Y, Sarner-Kanyas K, Ben-Asher E, Lancet D, Macciardi F, Lerer B (2012) Association of the type 2 diabetes mellitus susceptibility gene, TCF7L2, with schizophrenia in an Arab-Israeli family sample. PloS One 7(1):e29228

Alkelai A, Lupoli S, Greenbaum L, Giegling I, Kohn Y, Sarner-Kanyas K, Ben-Asher E, Lancet D, Rujescu D, Macciardi F (2012) Identification of new schizophrenia susceptibility loci in an ethnically homogeneous, family-based, Arab-Israeli sample. FASEB J 25(11):4011-4023

Greenbaum L, Alkelai A, Zozulinsky P, Kohn Y, Lerer B (2012) Support for association of HSPG2 with tardive dyskinesia in Caucasian populations. Pharmacogenomics J 12(6):513-520

Greenbaum L, Lifschytz T, Zozulinsky P, Broner EC, Slonimsky A, Kohn Y, Lerer B (2012) Alteration in RGS2 expression level is associated with changes in haloperidol induced extrapyramidal features in a mutant mouse model. Eur Neuropsychopharm 22(5):379-386

Lifschytz T, Broner EC, Zozulinsky P, Slonimsky A, Eitan R, Greenbaum L, Lerer B (2012) Relationship between Rgs2 gene expression level and anxiety and depression-like behaviour in a mutant mouse model: Serotonergic involvement. Int J Neuropsychop 15(09):1307-1318

Greenbaum L, Smith RC, Lorberboym M, Alkelai A, Zozulinsky P, Lifshytz T, Kohn Y, Djaldetti R, Lerer B (2012) Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients. Psychopharmacology (Berl) 220(3):519-528

Gesundheit B, Rosenzweig JP, Naor D, Lerer B, Zachor DA, Prochֳ¡zka V, Melamed M, Kristt DA, Steinberg A, Shulman C (2013) Immunological and autoimmune considerations of Autism Spectrum Disorders. J Autoimmun 44:1-7

Greenbaum L, Rigbi A, Lipshtat N, Cilia R, Tesei S, Asselta R, Djaldetti R, Goldwurm S, Lerer B (2013) Association of nicotine dependence susceptibility gene, CHRNA5, with Parkinson’s disease age at onset: Gene and smoking status interaction. Parkinsonism Relat Disord 19(1):72-76

Lotan A, Lifschytz T, Slonimsky A, Broner E, Greenbaum L, Abedat S, Fellig Y, Cohen H, Lory O, Goelman G (2014) Neural mechanisms underlying stress resilience in Ahi1 knockout mice: Relevance to neuropsychiatric disorders. Mol Psychiatry 19(2):243-252